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women who accessed emergency contraceptives for immediate use prescribed by community pharmacists in
British Columbia, Canada, between December 2000 and December 2002. Linked administrative healthcare data
were used to discern the timings ofmenses, unprotected intercourse, and any pregnancy-related health services.
A panel of experts evaluated the compatibility of observed pregnancies with the timing of events. The two regi-
mens were comparedwith statistical adjustments for potential confounding. Results: Among 7493women in the
cohort, 4470 (59.7%) received levonorgestrel and 3023 (40.3%) the Yuzpe regimen. There were 99 (2.2%) com-
patible pregnancies in the levonorgestrel group and 94 (3.1%) in the Yuzpe group (P = 0.017). The estimated
odds ratio for levonorgestrel compared with the Yuzpe regimen after adjusting for potential confounders was
0.64 (95% conﬁdence interval 0.47–0.87). Against an expected pregnancy rate of approximately 5%, the relative
and absolute risk reductions were 56.0% and 2.8%, respectively, for levonorgestrel and 36.7% and 1.8% for the
Yuzpe regimen. Conclusion: The levonorgestrel regimen is more effective than the Yuzpe regimen in routine
use. The data suggest that both regimens are less effective than has been observed in randomized trials.
© 2016 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Comparative effectiveness research
Emergency contraception
Emergency contraceptives
Levonorgestrel
Postcoital contraceptives
Pregnancy1. Introduction
Emergency contraceptives can potentially prevent pregnancy after
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gy and Obstetrics. Published by Elsavailable to women in some countries. According to a 2014 statement
of the International Consortium for Emergency Contraception [1], 22
countries do not import any product labeled as an emergency contra-
ceptive and have no product marketed speciﬁcally for this indication.
Even in countries where the levonorgestrel regimen is registered as an
emergency contraceptive, the product is not always routinely available
[1–3], and might not be available to women in a timely manner.
In countrieswhere nodedicated emergency contraceptive product is
available, combined oral contraceptives can be used to recreate the
Yuzpe regimen, which was the emergency contraceptive of choice in
the 1970s, 1980s, and 1990s. It consists of two doses, each containing
0.1 mg ethinyl estradiol and either 0.5 mg levonorgestrel or 1.0 mg
norgestrel, 12 h apart. The International Consortium for Emergency
Contraception statement [1] emphasizes the role of the Yuzpe regimen
in women without access to contraceptives designated for emergency
contraception, and advocates for communication of this information to
women and healthcare providers in relevant settings. From an interna-
tional perspective, the Yuzpe regimen offers critical emergency contra-
ceptive access to these women [1].
In randomized trials comparing the levonorgestrel and Yuzpe regi-
mens [4–6], enrollment was restricted to womenwith regular menstrual
cycleswho reportedly had only one act of intercoursewithin 48 or 72 h of
requesting an emergency contraceptive, which might not reﬂectevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license (http://
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the two regimens has not been compared on a large scale under condi-
tions of usual care, or amongwomenwith regular and irregularmenstru-
al cycles. The objective of the present studywas to estimate and compare
the effectiveness of the levonorgestrel and Yuzpe regimens under condi-
tions of routine clinical use.
2. Materials and methods
The present retrospective population-based study included women
who accessed either the levonorgestrel regimen (various brands, such
as Plan B [Paladin Labs, St-Laurent, Canada]) or the Yuzpe emergency
contraceptive regimen prescribed by community pharmacists in British
Columbia, Canada, between December 1, 2000, and December 31, 2002.
This study period was selected because treatment consent forms were
required during this period, after which relevant clinical and demo-
graphic informationwas not collected systematically in routinepractice.
The consent forms included age, the onset of the last menstrual period,
the date and time of the index act of unprotected intercourse for which
the emergency contraceptive was requested, the trade name and the
dispensing date and timeof the emergency contraceptive, the pharmacy
identiﬁcation code, and whether the emergency contraceptive was re-
quested for immediate use (after the index intercourse) or advance
use (after a future act of intercourse).
De-identiﬁed data were obtained from three linkable administrative
health dataﬁles: PharmaNet (all prescription drug dispensations in Brit-
ish Columbia),Medical Services Plan (physicians' fee-for-service billings
for outpatient services), and hospital separation records (services pro-
vided in hospital and clinic facilities). The PharmaNet data included
the drug name, strength, dosage form, and dispensing date, each
woman's local health area code, and the pharmacy's health area code.
TheMedical Services Plandata included diagnostic codes from the Inter-
national Classiﬁcation of Diseases, Ninth Revision, and physician service
billing codes [7]. The hospital separation data included the admission
date, the separation date, diagnostic codes, and procedure codes listed
under the Canadian Classiﬁcation of Diagnostic, Therapeutic, and Surgi-
cal Procedures [8]. The present researchwas approved by theUniversity
of British Columbia Clinical Research Ethics Board and the Children's
and Women's Health Centre Research Ethics Board.
Data for all pharmacist-prescribed emergency contraceptives over
the 25-month period were analyzed, excluding prescriptions for ad-
vance use. Because the consent forms could not be linked directly to
the other data ﬁles, each consent form was matched to its correspond-
ing PharmaNet prescription record by four criteria: age, product trade
name, dispensing date, and local health area of the dispensing pharma-
cy. To obtain unambiguous matches, records on each side of the match
had to include unique combinations of the four criteria. The study co-
hort comprised theﬁrst prescription for eachwomanwhose PharmaNet
record was matched to a consent form.
Pregnancy-related codes within 42 weeks after the dispensing date
and abortion-speciﬁc codes within 20 weeks were identiﬁed. These
timewindowswere anchored on the dispensing date because gestational
age could not be accurately determined from the study data. Clinical ex-
perts with long-term experience in diagnosing and billing for maternity
care services were consulted on relevant administrative codes.
The presence of a pregnancy compatible with the index act of inter-
course for which emergency contraceptive was sought (primary out-
come) was adjudicated by three experts. Time proﬁles were used to
illustrate the timing of the last menstrual period, intercourse, emergen-
cy contraceptive dispensing, and pregnancy-related codes in relation to
each other. When an abortion-related code was identiﬁed, the facility's
policy for service provision was included as a comment on the proﬁle
without identifying the facility. The experts were trained using sample
time proﬁles to develop a systematic approach to the adjudication of
cases for the presence of compatible pregnancy and induced abortion.
After discussing the sample cases and adopting a general approach,each expert adjudicated all cases independently. They then reconvened
to discuss cases with discordant adjudication. The experts weremasked
to the emergency contraceptive regimen throughout the adjudication
and discussion process.
Potential confounders related to fertility and/or sexual behavior for
which datawere available included age [9,10], time to receiving an emer-
gency contraceptive after intercourse [11], income [9], menstrual cycle
day of intercourse [10,12], 1-year history of pregnancy [9], 1-year history
of any emergency contraceptive dispensation, 5-year history of relevant
gynecologic conditions, 1-year history of hormonal contraceptive use,
and concurrent hormonal contraceptive use. Canadian census data were
used to retrieve the neighborhood income at the dissemination area
level [13]. Relevant gynecologic covariates included pelvic inﬂammatory
disease [14], endometriosis [14], ovarian dysfunction [14], ectopic preg-
nancy [15], infertility, and sterilization.
Compatible pregnancies were enumerated on the basis of the ﬁnal
majority vote of the three experts. Inter-rater agreement of adjudication
was measured with the Fleiss κ statistic using SPSS version 15.0 (SPSS,
Chicago, IL, USA) and David Nichols' macro [16]. The observed pregnan-
cy rates in the two regimen groups were compared using the χ2 test in
SPSS. P b 0.05 (two-sided) was considered statistically signiﬁcant.
Multivariate logistic regressionmodelingwas used to control for po-
tential confounding, with the selection of variables being guided by
prior information about the covariates and by the data [17]. The multi-
variate model was developed by adding one covariate at a time, begin-
ningwith covariates documented elsewhere [10] as clinically important
predictors of pregnancy that also had a signiﬁcant association with
pregnancy in the initial univariate analyses. Observations with missing
covariate data were excluded. The best model was selected on a balance
of model ﬁt (lower Akaike information criterion) and parsimony (fewer
variables) to obtain the adjusted odds ratio of pregnancy for the levo-
norgestrel regimen relative to the Yuzpe regimen.
Continuous variables were included as linear terms unless they
displayed a curvilinear relationship with pregnancy, in which case qua-
dratic terms were included with the linear terms based on the results of
univariate analyses [17]. Interaction and multicollinearity were assessed
as well.
Sensitivity analyses were conducted to evaluate the effect of addi-
tional variables and that of alternativemodel speciﬁcations. Onemodel-
ing strategy was to model each continuous variable as an array of
dichotomous categorical variables; another involved curve-smoothing
of logistic B-spline regression [18]. Regressionmodeling was conducted
using SAS version 9.2 (SAS Institute, Cary, NC, USA).
To emphasize clinically relevant outcomes, the effectiveness of each
regimen was assessed by comparing the observed pregnancy rate and
an expected pregnancy rate in both relative and absolute terms [19].
The expected pregnancy rates were estimated using pregnancy probabil-
ities publishedby Li et al. [12]. The traditional effectmeasure—the relative
risk reduction—was computed as follows: 1 – (observed pregnancy rate/
expected pregnancy rate) [19]. We also calculated the absolute risk re-
duction between the expected and observed pregnancy rates and the
number needed to treat (NNT).
3. Results
The study cohort comprised 7493 women (Fig. 1), including 4470
(59.7%) and 3023 (40.3%) women in the levonorgestrel and Yuzpe
groups, respectively. Characteristics of the women are shown in Table 1;
differences between the two groups were computed with Yuzpe as the
comparison group. Intercourse most frequently occurred near mid-cycle
and was less frequent near the beginning and end of the cycle (Fig. 2).
The records of 467 (6.2%) of the 7493 women screened positive for
pregnancy-related codes. The observed compatible pregnancy rate in
the cohort was 2.6% (193 pregnancies among 7493 women), with a
high degree of concordance among the three experts' adjudications
(Fleiss κ value 0.97). There were 99 (2.2%) compatible pregnancies in
PharmaNet records (n=14 110) Consent form records (n=13 579)
PharmaNet records with unique
combinations of the four matching criteria
(n=11 014)
Consent form records with unique
combinations of the four matching criteria 
(n=12 482)
Matched records (n=8622)
First prescription of each woman (n=7493)
Fig. 1. Procedure for matching PharmaNet records of emergency contraceptive
prescriptions and consent forms.
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The unadjusted odds ratio of pregnancy with the levonorgestrel regimen
comparedwith the Yuzpe regimenwas 0.71 (95% conﬁdence interval [CI]
0.53–0.94). In multivariate regression analysis, the age and the cycle day
of intercourse were added to the model with quadratic terms. After ad-
justment for potential confounders in the most parsimonious model
with the best ﬁt, the risk of pregnancy with the levonorgestrel regimen
was 36% lower relative to the Yuzpe regimen (odds ratio 0.64, 95% CI
0.47–0.87). Additional variables did not improve the model ﬁt substan-
tially, and there was no evidence of interaction or multicollinearity be-
tween covariates. Therefore, the ﬁnal model included the regimen type,
age, and cycle day of intercourse for the 6683 women (89.2% of the co-
hort) whose age and cycle day of intercourse were known. In sensitivity
analyses, alternative strategies for modeling age and the cycle day of in-
tercourse produced results similar to polynomial regression.
The effectiveness of the two regimens was estimated and calculated
in a number of ways to illustrate their comparative effectiveness
(Table 2). Against the estimated expected pregnancy rate of 5.0% in
the levonorgestrel group, the relative risk reduction was 56.0%, the ab-
solute risk reduction was 2.8%, and accordingly the NNT to prevent one
pregnancy was 36. For the Yuzpe regimen, the relative risk reduction
was 36.7%, the absolute risk reduction was 1.8%, and the NNT was 56.
4. Discussion
In the present population-based study, the observed pregnancy
rates were 2.2% and 3.1% in the levonorgestrel and Yuzpe groups, re-
spectively. The adjusted odds ratio of pregnancy was approximatelyTable 1
Characteristics of the women in the study cohort.a
Characteristic Levonor
(n = 44
Age, y 26.4 ± 7
Day of menstrual cycle on which unprotected intercourse occurred b 16.3 ± 7
Time to receive EC after unprotected intercourse, h c 25.0 ± 1
Dissemination-area-level neighborhood income, CAN$ d 31 140 ±
History of pregnancy within 1 year before the index EC 440 (9.8
History of speciﬁed gynecologic condition within 5 years before the index EC e 228 (5.1
History of any EC prescription within 1 year before the index EC 362 (8.1
Concurrent use of hormonal contraceptive f 308 (6.9
History of hormonal contraceptive prescription (excluding concurrent use)
within 1 year before the index EC f
703 (15
Abbreviation: EC, emergency contraceptive.
a Values are given as mean ± SD or number (percentage), unless indicated otherwise.
b Day number 1 is the ﬁrst day of the currentmenstrual cycle. For this estimation, informatio
for 4020 women who received levonorgestrel and 2663 who received the Yuzpe regimen.
c Information was available for 4312 women who received levonorgestrel and 2888 who re
d Information about average neighborhood income at the dissemination area level was availab
e Pelvic inﬂammatory disease, endometriosis, ovarian dysfunction, ectopic pregnancy, inferti
to capture relevant diagnostic, procedural, and billing codes.
f Theoretical concurrent use on the basis of having hormonal contraceptive prescription that ove
included PharmaNet records of oral contraceptive pills, medroxyprogesterone 150 mg/mL vials0.64, indicating that levonorgestrel is more effective than is the Yuzpe
regimen under conditions of routine use.
In a review published in 2012 [19], the average pregnancy rates were
1.7% (95% CI 1.2–2.2%) and 2.0% (95% CI 1.5–2.5%) in studies of women
treated with levonorgestrel or the Yuzpe regimen, respectively. The
two regimens have been compared in randomized trials [4–6]. The ﬁrst
[4] involved 880 women and found pregnancy rates of 2.4% (95% CI
0.8%–4.1%) and 2.7% (95% CI 1.0%–4.1%) in the levonorgestrel and
Yuzpe groups, respectively, after excluding womenwho had subsequent
acts of intercourse. A very small trial [6] of 122 women observed preg-
nancy rates of 0% and 8.3% in the levonorgestrel and Yuzpe groups, re-
spectively. The largest randomized trial (n = 1955) [5] observed
pregnancy rates of 1.0% (95% CI 0.5%–1.9%) and 2.9% (95% CI 1.9%–4.1%)
in the levonorgestrel and Yuzpe groups, respectively, after excluding
women who were pregnant at enrollment (risk ratio 0.36, 95% CI
0.17–0.73). The signiﬁcant association between regimen type and risk
of pregnancy in the present cohort study is consistent with the results
of the WHO trial [5]. However, the point estimates of the regimen-
speciﬁc pregnancy rates in the present study were higher, possibly be-
cause women who request emergency contraceptives under routine
practice conditions (compared with those in a clinical trial) have more
acts of unprotected intercourse before and/or after the index act for
which the emergency contraceptive is requested.
Levonorgestrel is better tolerated than is the Yuzpe regimen [4,5], and
despite its higher cost, it has, over the past decade, become regarded as
the oral emergency contraceptive of choice in many countries. The
present study provides further evidence that the levonorgestrel regimen
should continue to be preferred when a choice needs to be made be-
tween the two regimens during routine care. Nevertheless, because ac-
cess to emergency contraception is currently limited to the equivalent
of the Yuzpe regimen in some low-income countries [1,3], it is important
to recognize that it is less effective than the levonorgestrel regimen.
On the basis of the WHO trial [5], the levonorgestrel regimen has
beenwidely reported to be 85% effective [20,21]; however, evidence in-
dicates that the baseline (expected) pregnancy rates used to derive ef-
fectiveness in that trial and in other studies were overestimated
[22–24]. We selected the data by Li et al. [12] from a North Carolina
study group for estimating the expected pregnancy rates because the
women in that study had no known subfecundity, the method used by
the North Carolina group adjusted for variability in the day of ovulation,
and it did not require information about the women's cycle length [25].
The expected pregnancy rate in the present cohort was estimated to be
5%,which is slightly higher than the reported rate of 3.9% among 20 437gestrel regimen
70)
Yuzpe regimen
(n = 3023)
Difference between groups
(95% conﬁdence interval)
Total (n = 7493)
.9 24.7 ± 7.6 1.7 (1.3 to 2.0) 25.7 ± 7.8
.3 16.5 ± 7.7 −0.2 (−0.6 to 0.2) 16.3 ± 7.5
9.4 27.9 ± 19.2 −2.9 (−3.8 to−2.0) 26.2 ± 19.3
11 843 29 275 ± 8880 1866 (1342 to 2390) 30 396 ± 10 797
) 340 (11.2) −1.4% (−2.8% to 0.0%) 780 (10.4)
) 130 (4.3) 0.8% (−0.2% to 1.8%) 358 (4.8)
) 313 (10.4) −2.3% (−3.6% to 0.9%) 675 (9.0)
) 214 (7.1) −0.2% (−1.4% to 1.0%) 522 (7.0)
.7) 534 (17.7) −2.0% (−3.7% to−0.2%) 1237 (16.5)
n about themenstrual cycle day of unprotected intercourse (day 1 to day 40) was available
ceived the Yuzpe regimen.
le for 4061 womenwho received levonorgestrel and 2695 who received the Yuzpe regimen.
lity, and sterilization.Medical Services Plan and hospital separation recordswere examined
rlapped the dispensing date for the index emergency contraceptive. Hormonal contraceptives
, and levonorgestrel-releasing intrauterine systems.
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Fig. 2. Number of pregnancies expected after unprotected intercourse on menstrual cycle days 1–40 among 6683 women in the cohort with available information.
345V.W.Y. Leung et al. / International Journal of Gynecology and Obstetrics 133 (2016) 342–346emergency contraceptive seekers in another study [26]. However, most
women evaluated by theNorth Carolina study groupwere trying to con-
ceive [12], and so there might be behavioral differences that could pos-
sibly result in a higher overall probability of pregnancy compared with
women seeking emergency contraceptives.
The effectiveness of emergency contraceptives is typically presented
as a relative reduction in pregnancy risk [19]. However, it is becoming
more common in general to report absolute treatment effects, which
are more clinically meaningful and less susceptible tomisinterpretation
than relative risk reduction [19]. Thepresent study showed that,with an
expected pregnancy rate of approximately 5%, the absolute reduction of
pregnancy risk was only 2–3%. This magnitude of effect is probably sur-
prising to those who have anticipated greater effectiveness on the basis
of earlier reports of substantial relative risk reductions [19].
The present studywas limited by the use of administrative data from
only one geographic region. Some pregnancies might not have been
documented (e.g. if women had left the province). However, the num-
ber of missed pregnancies in the levonorgestrel group would have to
be substantially more than in the Yuzpe group to affect the association
of treatmentwith pregnancy. It is possible that the experts misclassiﬁed
nonpregnant cases as pregnant and vice versa. However, because the
experts were masked to the regimen, any outcome misclassiﬁcation
would probably have been non-differential between the two groups.
As in other cohort studies, the present multivariate analysis included
only measured covariates. Residual confounding stemming from un-
measured confounders (e.g. body mass index) and/or inadequatelyTable 2
Treatment effect of emergency contraceptives.
Effect measure Levonorgestrel
regimen (n = 4470)
Yuzpe regimen
(n = 3023)
Expected pregnancy rate (risk), % a 5.0 4.9
Observed pregnancy rate (risk), % 2.2 3.1
Relative risk reduction, % 56.0 36.7
Absolute risk reduction, % 2.8 1.8
Number of women needed to treat
to prevent one pregnancy
36 56
a The expected pregnancy rate in the absence of an emergency contraceptive was esti-
mated on the basis of the set of conception probabilities developed by Li et al. [12]. For the
present estimation, 6683 (89.2%)women in the cohort reported that the index act of inter-
course occurred between cycle days 1 and 40. The expected pregnancy rate among these
women was extrapolated to the entire cohort for calculations of relative and absolute risk
reductions and the number needed to treat.controlled confounding could have contributed to the observed differ-
ence between the two regimens. However, the observed ﬁndings are
unlikely to be explained entirely by confounding because the magni-
tude of any association of confounders with the regimen type and
with pregnancy would have to be so strong as to be clinically implausi-
ble to nullify the effect of the levonorgestrel regimen. In view of the
strength of association between the regimen type and pregnancy after
adjustment for imbalances in the measured covariates, the levonorges-
trel regimen was deemed to be the more effective of the two. Thus, le-
vonorgestrel should be the preferred regimen where it is available.
Postmarketing comparative effectiveness research is important for
evaluating medications under real-world usage conditions [27]. In the
present study of almost 7500 women, the levonorgestrel regimen was
more effective than the Yuzpe regimen. Against an expected pregnancy
rate of approximately 5%, the absolute reduction in the pregnancy rate
was only 2%–3%. More effective approaches, including regular contracep-
tion and other forms of emergency contraception such as intrauterine de-
vices and ulipristal acetate, should be considered and personalized
according to eachwoman's preferences. As has been recommended, levo-
norgestrel and other methods should be made more widely available,
along with education of women and healthcare providers.
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